Research Analysts Issue Forecasts for Biogen FY2025 Earnings

Biogen Inc. (NASDAQ:BIIB) – Equities researchers at Zacks Research lowered their FY2025 earnings per share (EPS) estimates for Biogen in a research report issued on Thursday, November 13th. Zacks Research analyst Team now anticipates that the biotechnology company will post earnings per share of $14.78 for the year, down from their prior forecast of $15.98. The consensus estimate for Biogen’s current full-year earnings is $15.83 per share. Zacks Research also issued estimates for Biogen’s Q4 2025 earnings at $1.48 EPS, Q1 2026 earnings at $3.32 EPS, Q4 2026 earnings at $3.53 EPS, FY2026 earnings at $14.49 EPS, Q1 2027 earnings at $3.31 EPS and FY2027 earnings at $15.32 EPS.

Several other analysts also recently issued reports on the company. Stifel Nicolaus upgraded Biogen from a “hold” rating to a “buy” rating and upped their price objective for the company from $144.00 to $202.00 in a research report on Thursday, November 6th. William Blair reissued an “outperform” rating on shares of Biogen in a research note on Wednesday, September 24th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Biogen in a research note on Thursday, November 13th. Wall Street Zen downgraded shares of Biogen from a “buy” rating to a “hold” rating in a report on Sunday, November 9th. Finally, HC Wainwright upped their price objective on shares of Biogen from $187.00 to $194.00 and gave the company a “buy” rating in a research note on Friday, August 1st. Ten equities research analysts have rated the stock with a Buy rating, sixteen have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $177.46.

Biogen Price Performance

BIIB stock opened at $168.83 on Monday. The stock’s 50 day moving average price is $149.34 and its 200 day moving average price is $137.12. The firm has a market cap of $24.77 billion, a P/E ratio of 16.14, a PEG ratio of 1.17 and a beta of 0.10. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.79 and a current ratio of 2.50. Biogen has a 1 year low of $110.04 and a 1 year high of $170.78.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings data on Thursday, October 30th. The biotechnology company reported $4.81 EPS for the quarter, beating analysts’ consensus estimates of $3.89 by $0.92. Biogen had a net margin of 15.31% and a return on equity of 13.85%. The firm had revenue of $2.53 billion for the quarter, compared to analysts’ expectations of $2.34 billion. During the same period in the prior year, the company earned $4.08 EPS. The firm’s revenue was up 2.8% on a year-over-year basis. Biogen has set its FY 2025 guidance at 14.500-15.00 EPS.

Hedge Funds Weigh In On Biogen

Large investors have recently modified their holdings of the company. Advisory Services Network LLC lifted its stake in shares of Biogen by 3.9% in the 3rd quarter. Advisory Services Network LLC now owns 1,792 shares of the biotechnology company’s stock valued at $251,000 after purchasing an additional 68 shares in the last quarter. Camelot Portfolios LLC purchased a new position in Biogen in the third quarter valued at approximately $294,000. Morningstar Investment Management LLC acquired a new position in Biogen during the third quarter valued at approximately $2,631,000. NewEdge Advisors LLC grew its stake in Biogen by 241.9% during the third quarter. NewEdge Advisors LLC now owns 9,138 shares of the biotechnology company’s stock worth $1,280,000 after buying an additional 6,465 shares during the period. Finally, Krensavage Asset Management LLC acquired a new stake in shares of Biogen in the third quarter worth $1,401,000. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, insider Priya Singhal sold 517 shares of the company’s stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $133.55, for a total transaction of $69,045.35. Following the completion of the sale, the insider directly owned 5,772 shares in the company, valued at $770,850.60. This represents a 8.22% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. 0.18% of the stock is owned by corporate insiders.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.